Voya Investment Management LLC Sells 2,462 Shares of Quest Diagnostics Incorporated (NYSE:DGX)

Voya Investment Management LLC lessened its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 6.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,498 shares of the medical research company's stock after selling 2,462 shares during the period. Voya Investment Management LLC's holdings in Quest Diagnostics were worth $5,054,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Price T Rowe Associates Inc. MD raised its holdings in Quest Diagnostics by 42.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,490,278 shares of the medical research company's stock worth $828,265,000 after purchasing an additional 1,637,525 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Quest Diagnostics by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 2,690,021 shares of the medical research company's stock valued at $404,764,000 after buying an additional 73,368 shares during the period. JPMorgan Chase & Co. increased its holdings in Quest Diagnostics by 60.4% in the fourth quarter. JPMorgan Chase & Co. now owns 2,433,913 shares of the medical research company's stock worth $367,180,000 after buying an additional 916,898 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC boosted its holdings in Quest Diagnostics by 1.2% in the fourth quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 2,268,990 shares of the medical research company's stock worth $342,300,000 after purchasing an additional 26,214 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Quest Diagnostics during the 4th quarter worth about $191,823,000. Institutional investors own 88.06% of the company's stock.

Quest Diagnostics Stock Performance

Shares of Quest Diagnostics stock traded down $1.06 during trading on Tuesday, hitting $176.51. 117,391 shares of the stock were exchanged, compared to its average volume of 961,224. The company has a current ratio of 1.10, a quick ratio of 1.02 and a debt-to-equity ratio of 0.82. The company has a fifty day moving average price of $169.51 and a 200-day moving average price of $162.36. Quest Diagnostics Incorporated has a 1-year low of $135.35 and a 1-year high of $179.32. The stock has a market capitalization of $19.70 billion, a price-to-earnings ratio of 22.95, a price-to-earnings-growth ratio of 2.16 and a beta of 0.52.

Quest Diagnostics (NYSE:DGX - Get Free Report) last released its earnings results on Tuesday, April 22nd. The medical research company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.15 by $0.06. Quest Diagnostics had a net margin of 8.80% and a return on equity of 15.07%. The firm had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.63 billion. As a group, equities analysts predict that Quest Diagnostics Incorporated will post 9.7 EPS for the current fiscal year.

Insider Buying and Selling

In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 604 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $170.99, for a total transaction of $103,277.96. Following the completion of the sale, the senior vice president now directly owns 39,845 shares of the company's stock, valued at approximately $6,813,096.55. The trade was a 1.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Mark E. Delaney sold 403 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $164.30, for a total value of $66,212.90. Following the completion of the transaction, the senior vice president now owns 4,624 shares in the company, valued at $759,723.20. This represents a 8.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 55,903 shares of company stock valued at $9,460,221 over the last quarter. Insiders own 8.16% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on DGX shares. StockNews.com downgraded Quest Diagnostics from a "buy" rating to a "hold" rating in a research report on Thursday, February 6th. Redburn Partners set a $195.00 target price on Quest Diagnostics in a research report on Wednesday, April 2nd. Citigroup cut shares of Quest Diagnostics from a "buy" rating to a "neutral" rating and set a $185.00 price objective on the stock. in a research note on Tuesday, March 4th. UBS Group lifted their price target on Quest Diagnostics from $166.00 to $170.00 and gave the company a "neutral" rating in a report on Monday, February 3rd. Finally, Mizuho upped their price target on Quest Diagnostics from $178.00 to $189.00 and gave the company an "outperform" rating in a research note on Wednesday, April 9th. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $185.73.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.